PHVS
HealthcarePharvaris N.V. · Biotechnology · $2B
What is Pharvaris N.V.?
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for hereditary angioedema, a rare and potentially life-threatening condition. Headquartered in Leiden, the Netherlands, the company operates across Europe and the United States.
Pharvaris is building a pipeline centered on PHA121, a small molecule bradykinin B2-receptor antagonist designed to address hereditary angioedema. The company is advancing two formulations — PHVS416, an on-demand soft capsule for acute HAE attacks, and PHVS719, a prophylactic extended-release tablet. Both candidates are in active clinical trials. Revenue generation depends on successful trial outcomes and eventual regulatory approval, which means the company currently operates without commercial product sales.
Pharvaris was incorporated in 2015 and is based in Leiden, the Netherlands.
- PHVS416 — on-demand oral capsule for acute HAE attacks (Phase 2)
- PHVS719 — prophylactic extended-release tablet for HAE (Phase 1)
- PHA121 platform — bradykinin B2-receptor antagonist technology
Is PHVS a Good Stock to Buy?
UQS Score rates PHVS as Poor overall, reflecting the early-stage nature of the business and the uncertainties inherent in clinical development.
Among the five pillars, Risk comes in at a Neutral rating — the least concerning area — suggesting the company's balance sheet and near-term financial structure are not in immediate distress relative to its stage.
Quality, Moat, and Growth all register as Weak, which is typical for pre-revenue biotechs but signals meaningful uncertainty. Valuation is rated Elevated, meaning the market may already be pricing in optimistic outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PHVS pay dividends?
No — Pharvaris N.V. does not currently pay a dividend.
Pharvaris does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward funding clinical trials and advancing the pipeline. Income-focused investors should not expect distributions in the near term — reinvestment into R&D is the defining financial posture at this stage.
When does PHVS report earnings?
Pharvaris reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue biotech, quarterly reports focus on cash runway, clinical milestones, and operating expenses rather than traditional revenue or profit metrics. Trial progress updates and pipeline announcements tend to move the stock more than earnings figures alone.
For the most recent quarter's results and pipeline updates, visit Pharvaris's investor relations page directly.
PHVS Price History
+42.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pharvaris N.V.?
Based on Pharvaris N.V.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PHVS Long-term Outlook
The fundamental outlook for Pharvaris is shaped primarily by clinical trial outcomes rather than near-term financial performance. With Growth and Quality both rated Weak, the path to value creation runs through regulatory milestones. The Elevated Valuation rating suggests the stock already reflects meaningful optimism, which can amplify downside if trial data disappoints. The Neutral Risk rating offers some reassurance that the company is not in immediate financial distress.
Growth drivers
- Positive Phase 2 data readouts for PHVS416 or PHVS719
- Advancement of the PHA121 platform toward later-stage trials
- Growing clinical and commercial interest in oral HAE therapies
Key risks
- Clinical trial failure or unfavorable safety data
- Elevated valuation leaves limited margin of safety
- Dependence on external financing before any commercial revenue
PHVS vs Peers
Pharvaris competes in the rare disease and specialty biotech space alongside companies at varying stages of development.
Tyra focuses on precision medicine for fibroblast growth factor receptor-driven diseases, targeting a distinct rare disease mechanism from Pharvaris's bradykinin pathway approach.
Vericel is a commercial-stage rare disease company with approved cell therapy products, giving it a revenue base that Pharvaris has yet to establish.
Galapagos is a larger European biopharmaceutical company with a broader pipeline and more advanced commercial infrastructure than Pharvaris currently possesses.
Frequently Asked Questions
What does Pharvaris do?
Pharvaris is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema, a rare genetic condition causing severe swelling episodes. Its pipeline centers on the PHA121 platform, with two formulations — one for acute attacks and one for daily prevention — currently in clinical trials.
Does PHVS pay dividends?
No, Pharvaris does not pay a dividend. The company is pre-revenue and directs its capital toward clinical development. Shareholders should not expect income distributions until the business reaches a commercial stage, which depends on successful trial and regulatory outcomes.
When does PHVS report earnings?
Pharvaris reports on a quarterly basis. Because the company has no commercial revenue, reports focus on cash position, operating expenses, and clinical milestones. Check Pharvaris's investor relations page for the most current reporting schedule and recent results.
Is PHVS a good stock to buy?
UQS Score rates PHVS as Poor overall, driven by Weak ratings across Quality, Moat, and Growth, alongside an Elevated Valuation. This profile reflects the high uncertainty of clinical-stage biotech investing. The full pillar breakdown is available to UQS Pro members.
Is PHVS overvalued?
The UQS Valuation pillar for PHVS is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about clinical success. For pre-revenue biotechs, valuation is heavily tied to pipeline probability rather than current financials.
How does PHVS compare to its competitors?
Compared to peers like Vericel, which already has commercial products, Pharvaris is at an earlier stage with no approved therapies. Larger European biotechs like Galapagos have broader pipelines and more resources. Pharvaris's differentiation lies in its oral, small-molecule approach to HAE treatment.
What is PHVS's market cap bracket?
Pharvaris is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is common for clinical-stage rare disease biotechs.
Who founded Pharvaris?
Pharvaris was incorporated in 2015. Founding and leadership details are publicly available through the company's official website and regulatory filings, which provide the most accurate and current information on its history and management team.
Is PHVS a long-term quality indicator?
From a long-term quality perspective, PHVS currently scores as Poor on the UQS composite. Quality and Moat are both rated Weak, which reflects the absence of commercial revenue and durable competitive advantages at this stage. Long-term quality potential depends on clinical and regulatory progress.
What is the main competitive advantage of Pharvaris?
Pharvaris's potential advantage lies in its oral, small-molecule approach to hereditary angioedema — a market historically served by injectable therapies. If clinical trials confirm efficacy and tolerability, an oral option could offer meaningful differentiation. However, that advantage remains unproven until regulatory approval.
What sector does PHVS belong to?
Pharvaris operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals focused on rare diseases. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare quality profiles across the sector.
Unlock Full PHVS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare PHVS against rare disease biotech peers
- ✓Track pipeline risk through the UQS Risk pillar
- ✓Get the full analyst view available to Pro members
Pro Analysis
PHVS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 18.3 | 0.0 | 36.0 | 0.0 | 61.6 | 0.0 | +0.5 |
| May 10, 2026 | 17.8 | 0.0 | 36.0 | 0.0 | 58.9 | 0.0 | +1.9 |
| May 9, 2026 | 15.9 | 0.0 | 36.0 | 0.0 | 46.2 | 0.0 | -1.9 |
| Apr 9, 2026 | 17.8 | 0.0 | 36.0 | 0.0 | 58.9 | 0.0 | +0.5 |
| Apr 2, 2026 | 17.3 | 0.0 | 36.0 | 0.0 | 55.3 | 0.0 | — |
PHVS — Pillar Breakdown
Quality
— 0.0/100 (25%)Pharvaris N.V. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Pharvaris N.V. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 61.6/100 (15%)Pharvaris N.V. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Pharvaris N.V. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 36/100 (25%)Pharvaris N.V. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PHVS.
Score Composition
Financial Data
More Stock Analysis
How is the PHVS UQS Score Calculated?
The UQS (Unified Quality Score) for Pharvaris N.V. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pharvaris N.V.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pharvaris N.V. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.